EpiGro1000 - Swinney Nutrition

$ 119.99

Brief Summary of Epi-Gro1000's Ingredients


Epi-Gro1000 is the premier Epicatechin / Catechin supplement containing 1000 mg of Epicatechin per 2 capsules serving and 60 servings per bottle (60,000 mg of Epicatechin per bottle), which more than triples the amount of Epicatechin in the other leading brands. 

Green Tea Extract (50% EGCG) and Huperzine A:

Additionally, 400 mg of Green Tea Extract standardized to 98% Polyphenols and 50% EGCG providing 200 mg EGCG Catechins to each 2 capsules serving with a synergistic 200 mcg of Huperzine A.

The two daily servings of Epi-Gro1000 provides: 

  • 2000 mg of (-)-Epicatechin(Epicatechin Extract Cocoa Beans)
  • 800 mg of Green Tea Extract
    • (50% EGCG = 400 mg of EGCG Catechins)
  • 400 mcg Huperzine A


Ingredient Dosing Questions


If the industry standard is ~ 300 mg to 600 mg of Epicatechin per day and other companies only use ~ 300 mg of Epicatechin per serving, why did Swinney Nutrition decide to use such a high dose 2000 mg per day of Epicatechin (1000 mg x 60 servings)?


Brief Answer (Detailed Reference Based Answer Below):

Swinney Nutrition’s Epi-Gro1000 uses a high dose of Epicatechin (2000 mg Epicatechin per day) because that is the dose we associated with the most consistent body recomposition results.  


Why would an individual supplement with Epi-Gro1000?

Brief Answers (Detailed Reference Based Answer Below):

The shortest answer:

Body Recomposition.

The slightly longer answer:

Generally, Epi-Gro1000 can be referred to as a natural-anabolic.  The main ingredients may be recognized as natural because they have been found in cocoa, teas, berries, apples, and grape seeds.  Thus, they may be viewed as anabolic because clinical studies have associated them with the molecular processes related to skeletal muscle growth.  Therefore, If an individual is looking for a non-hormonal supplement to enhance muscle growth and fat loss, then Epi-Gro1000 should be at the top of their list.

Brief Epi-Gro1000 Summary 

(Detailed Reference Based Summary Below):

Overall, Epi-Gro1000 has been formulated to increase muscle and reduce fat through the mechanisms of reducing myostatin and somatostatin inhibition.

Epigro1000 also increases insulin sensitivity, and nutrient partitioning, as well. The favorable changes in body composition will also be accompanied by improvements in muscle contraction, growth and differentiation.

Suggested Use

As a dietary supplement, take 2 capsules (1 serving), with or without food, twice per day and separated by 4 to 6 hours. 

Do not exceed 6 capsules in a 24-hour period unless directed otherwise by a healthcare professional.


Detailed Scientific and Reference Based Information


How do the ingredients in Epi-Gro1000 enhance muscle growth and fat loss?



Since humans are complex dynamic systems with different homeostatic environments and adaptive constraints, isolating the exact reason Epi-Gro1000 may produce positive body recomposition effects across the general population is nearly impossible.  But we can identify the potential mechanisms associated with Epi-Gro1000’s ingredients and body recomposition in the clinical literature. 


If an individual wants to understand the potential mechanisms associated with a supplement, then they must begin by developing a solid base of foundational knowledge for each ingredient.  While Epi-Gro1000’s main ingredients (Epicatechin and EGCG Catechins) are generally classified as polyphenols, they are specifically classified as flavanols in the polyphenol subgroup called flavonoids.  Therefore, it may be advantageous to briefly discuss each category and highlight some of the relevant clinical literature regarding the potential health promotion and human performance benefits.


Polyphenols are naturally occurring secondary metabolites found in fruits, vegetables, and herbs that may have health promotion and human performance benefits. [1.]  Various epidemiological studies on animals and humans have demonstrated that polyphenols have antioxidant and anti-inflammatory qualities that could provide a positive effect against inflammation [2.], neurodegenerative diseases [2.] [3.] [4.] [5.] [6.] [7.] [8.] [9.] [10.] [11.] , cancer [2.] [11.] [12.] [13.] [14.] [15.] [16.], cardiovascular health [11.] [17.], cholesterol [2.] [14.] [15.] [18.] [19.] [20.] [21.], type 2 diabetes [3.] [22.] [23.] [24.], and obesity [12.] [17.] [22.] [23.] [24.] [25.] [26.]. 

The broad category of polyphenols is divided into four subgroups: flavonoids, lignans, phenolic acids, and stilbenes. [27.]  Multiple studies have demonstrated potential benefits (lower risk for coronary heart disease [28.] [29.] [30.] [31.], cardiovascular disease [29.] [31.], and stroke [32.] associated with regular consumption of dietary flavonoids. 

The polyphenol subgroup called flavonoids is further classified into six categories: flavones, flavanones, flavonols, flavanols, isoflavones, and anthocyanidins. [33.]  Flavanols are bioactive compounds derived from plants, teas, or cocoa [34.] [35.] that seem to have a positive effect on vascular / cardiovascular health and quality of life [36.] [37.].


Since Epi-Gro1000’s ingredients within the specific category of flavanols have demonstrated the ability to rapidly enhance vasodilation in peripheral arteries and improve endothelial function. [38.] [39.], it is easy to understand how individuals experience immediate physiological benefits.  While these physiological effects vary based on genetics, body size, and dosage, there may also be affected by interactions with other compounds or supplements.  For example, the methylxanthine known as caffeine seems to increase Epicatechin absorption and enhance its overall effects.  Since Epicatechin is the main ingredient of Epi-Gro1000 (1000 mg of Epicatechin per 2 capsules serving of Epi-Gro1000), consuming a serving of caffeine with a serving of Epi-Gro1000 may potentiate the effects.  In my opinion, this may be similar to the potentiating effect that caffeine has on aspirin. [40.] [41.]  However, consuming caffeine with Epi-Gro1000 is not mandatory to get the desired effects.


Throughout history studying indigenous people of specific regions has provided useful information to the nutrition and supplementation industry.  For example, in the 1970s, researchers studying the indigenous Greenland Eskimos discovered a potential link between omega-3 fatty acids (EPA and DHA) and heart health. [42.] [43.] [44.] [45.] [46.]  These initial investigations laid the foundation for thousands of clinical studies involving omega-3 fatty acids.

Another example involves Epi-Gro1000’s primary ingredient Epicatechin.  In the late 1990s, research teams discovered that Kuna Indians of the Caribbean Coast of Panama seemed to have a reduced frequency of cardiovascular disease and very low blood pressure [47.]  Since 24-hour food logs and urine collections indicated a sodium and chloride intake that exceeds most western populations [48.], researchers initially thought these individuals were genetically protected.  However, when researchers examined the Kuna Indians that migrated to urban areas, they found hypertension to be common and blood pressure to rise significantly with age.  The researchers quickly realized the observed cardiovascular health and blood pressure was environmental and not genetic.  Once the researchers performed a comprehensive dietary assessment, they found the hunter-gatherer island-dwelling Kuna consumed ~ 10 times more cocoa (~ 1880 mg of flavanols) per day than the urban-dwelling Kuna Indians. [47.] [49.]  Please do not misinterpret cocoa as chocolate.  Chocolate is a highly refined commercial product that typically lacks the important flavanol information on its label.  Cocoa or cacao is the fermented seed of Theobroma cacao tree.  In general, the raw unprocessed seed or bean contains the highest flavanol content.  Unfortunately, the flavanol content decreases as the seed or bean is refined and processed.  Since the Kuna prepare their cocoa drink in two steps (Step 1: grinding raw cacao beans, Step 2: boil ground cacao beans with a banana and strain the remaining solids prior to drinking), they consume significantly higher levels of flavanols than most.  A 2009 study estimated that the average cocoa consumption of the Kuna provides ~ 900 mg per day of the flavanol Epicatechin [50.]  If the main flavanol in cocoa is Epicatechin [51.] and clinical studies show that individuals receive the same nitric oxide and vasodilator response from Epicatechin and flavanol-rich cocoa [39.], then it may be the key mediator of cocoa’s beneficial effects.  In general, nitric oxide performs a multitude of biological functions and its bioactivity can be linked to numerous diseases. [52.]  If an individual is experiencing poor health from a lack of nitric oxide synthesis, then consuming a sufficient amount of the flavanol Epicatechin may provide a beneficial stimulus to the system.  In my opinion, if an individual becomes aware of this small slice of history on the flavanol Epicatechin, then they are more likely to appreciate its potential application and benefits.


One serving (2 capsules) of Epi-Gro1000 provides more Epicatechin (1000 mg) than the indigenous people of Kuna consumed in an entire day (~ 900 mg).  Therefore, if an individual wants to consume as much Epicatechin as the Kuna for the potential health promotion benefits, then one serving (2 capsules) of Epi-Gro1000 per day will satisfy the Epicatechin milligram requirements.



Does the main ingredient in Epi-Gro1000, Epicatechin, have any other potential benefits?



Overall, multiple studies have provided mechanistic evidence for polyphenols à flavonoids à flavanols à Epicatechin’s potential health promotion or human performance effects.  For example:


Potential Human Performance Mechanisms or Effects

  • Increased Follistatin and Decreased Myostatin [53.]
  • Improved Skeletal Muscle Mitochondria (in Patients with Heart Failure and Type 2 Diabetes) [54.]
  • Increased Exercise Performance and Exercise Capacity [55.]
  • Improves Aerobic Metabolism Capacity and Skeletal Muscle Oxidative Capacity [55.]


Potential Health Promotion Mechanisms or Effects

  • Increased Endothelial Cell’s Nitric Oxide Production [56.]
  • Reduced Myocardial Injury [57.]
  • Unique Cardioprotective Effects of Sustained Long-Term Use (Reduced Myocardial Infarct Size, Reduced Epicardial Scar Stains, and Improved Left Ventricular Morphometry) [58.]
  • Cardioprotective through preservation of mitochondrial function [59.]
  • Cardioprotective through free radical scavenging and antioxidant effects [60.]



Does the secondary ingredient in Epi-Gro1000, Green Tea Extract 400 mg (50% EGCG = 200 mg), have similar benefits as well?



In general, the categories of polyphenols à flavonoids à flavanols à Green Tea Extract (50% EGCG Catechins) have many potential health promotion and human performance properties.  In Epi-Gro1000, the secondary ingredient is generally referred to as Green Tea Extract.  More specifically, Swinney Nutrition’s formula uses a 50% EGCG extract of Catechins.  As mentioned above, a 50% EGCG extract of the 400 mg Green Tea Extract per 2 capsules serving provides 200 mg of EGCG Catechins per 2 capsules serving



 Question :

What is so special about 50% EGCG Catechins in Green Tea Extract?


 Answer :

EGCG, (-)-epigallocatechin-3-gallate, seems to be the most potent and studied bioactive ingredient in green tea.  Over the last thirty years, numerous clinical studies have associated green tea catechins with possible health promotion and human performance benefits.  For example:


  • Anti-cancer [61.] [62.] [63.] [64.] [65.] [66.] [67.] [68.] [69.] [70.] [71.] [72.]
  • Anti-Oxidant [73.]
  • Metal Chelating [74.] [75.]
  • Anti-Inflammatory [75.] [76.] [77.]
  • Anti-Microbial, Anti-Viral [78.] [79.] [80.]
  • Anti-Diabetic [81.] [82.]
  • Anti-Obesity [83.] [84.] [85.]
  • Neuroprotective [86.] [87.] [88.] [89.] [90.]


Question :

Understandably, there are numerous potential health promoting benefits of supplementing with Green Tea Extract, 50% EGCG.  In regard to human performance and body recomposition, how does this ingredient enhance an individual’s efforts?


 Answer :

This answer may vary slightly due to an individual’s genetics, training, nutrition, and supplementation protocols.  Beginning with the general information from animal models, green tea catechins demonstrated the potential to improve energy expenditure and fat metabolism. [91.] [92.] [93.]  Obviously, animals and humans are different, but acknowledging this information provides insight on the potential benefits of this ingredient.  In randomized controlled trails on obese humans, this ingredient improved weight loss and body recomposition. [94.] [95.] [96.] [97.] [98.]  In addition to the randomized controlled trials, two systematic reviews (2012 [99.] and 2017 [100.]) and one meta-analysis (2019 [101.]) support the potential fat loss benefits of green tea extract EGCG.  While green tea extract EGCG catechins may not work for all humans, the available clinical literature seems to suggest that it has the potential to help with fat loss.


Question :

While it seems obvious that this ingredient enhances fat loss, can Green Tea Extract, 50% EGCG also help with muscle growth?


 Answer :

While it has the potential to enhance specific mechanisms related to skeletal muscle hypertrophy, it is important to remember that individual responses can vary greatly, and context is key.  This ingredient may improve specific mechanisms related to skeletal muscle hypertrophy, but an individual needs to supply adequate protein (all 20 amino acids + auxiliary amino acids), complex carbohydrates (glucose à glycogen), medium chain triglyceride (C8 – Caprylic Acid, also known as CapTri Ò) and critically essential fatty acids (EPA, DHA, AA).  If an individual has checked all the nutritional boxes and training boxes for skeletal muscle growth, then they can consider how this specific ingredient may apply to their current training or nutrition protocol.

In my experience, the individuals that supplement with Epi-Gro1000 begins to develop skeletal muscle that appears rounder, fuller, thicker, and more cartoonish or bubbly.  While describing muscles as rounder, fuller, bubbly or cartoonish may sound weird, they seem to accurately describe my visual observation.  Then when Epi-Gro1000 was released to the public, I began to receive customer feedback (emails, text, and phone calls) describing a constant pumped, round, and full look to the skeletal muscles.  As mentioned earlier, Epi-Gro1000 contains 1000 mg of Epicatechin per 2 capsules serving and this ingredient is heavily linked to increased nitric oxide and blood flow, but there also seems to be a synergistic effect from the additional 400 mg of green tea extract (50% EGCG catechins).  In my opinion, this enhanced appearance may be linked to green tea extracts effect on glucose absorption and glycogen synthesis. 


In clinical studies, green tea extract catechins have demonstrated the ability to regulate glucose absorption via glucose transporter genes and insulin signaling pathways. [102.] [103.] [104.] [105.]  The overall effect of these molecular mechanisms is to increase the liver and skeletal muscle’s glucose uptake and glycogen storage.  If an individual’s skeletal muscle glycogen uptake is enhanced, then they will have the appearance described above.  Therefore, the combination of ingredients in Epi-Gro1000 synergistically enhances multiple aspects of body recomposition and appearance.


Question :

What is Huperzine A?


 Answer :

Huperzine A is a biologically active compound from the plant Huperzia serrata, referred to as “Qian Ceng Ta”, that has been used for centuries in Chinese Medicine. [106.] [107.] [108.]  This molecule seems to have the ability to penetrate the blood-brain-barrier and act as a reversible and selective acetylcholinesterase inhibitor. [109.] [110.] [111.] [112.] [113.] [114.]  Basically, this means that Huperzine A has the ability to increase levels of acetylcholine by preventing an enzyme from breaking down circulating acetylcholine.  Since acetylcholine is a neurotransmitter used in muscle contraction and learning, supplementing with Huperzine A may enhance available acetylcholine for training efforts.


Question :

Why is Huperzine A used in Epi-Gro1000?


 Answer :

Huperzine A is used in Epi-Gro1000 for multiple reasons.

Anecdotally, some physique enthusiasts have credited the synergistic combo of EGCG and Huperzine A with strengthening somatostatin inhibitors to their receptors and improving circulating growth hormone.  While this observation is purely anecdotal, individuals that use peptides like HGH (human growth hormone), GHRH (Growth Hormone Releasing Hormones), GHRP (Growth Hormone Releasing Peptides), GH oral (MK-677), and various other peptides (IGF-1, MGF, etc.) seem to quickly break through plateaus or stagnant periods of growth after the addition of Epi-Gro1000.  Understandably, it is nearly impossible to know if the results are from the combo of EGCG and Huperzine A strengthening somatostatin inhibition or the large dose of Epicatechin included in the Epi-Gro1000 formula.  In my experience, as long as an individual breaks through their current plateau or improves their overall body composition (without deleterious health effects), they don’t care if the results are from the exact dose of Epicatechin, EGCG, or Huperzine A, or the combo of all three ingredients.  


Unfortunately, the relationship between training and the central nervous system, peripheral nervous system, NGF (Nerve Growth Factors), skeletal muscle innervation potential, etc. is rarely discussed.  While these subjects may be rarely discussed, forming an understanding is highly beneficial for enhancing training performance and results (especially for the individuals using non-conventional or exotic supplements).  Huperzine A may not be considered non-conventional or exotic to some individuals, but some of the potential mechanisms may be outside of the traditional understanding or application of this ingredient.

As mentioned above, Huperzine A is a potent and selective acetylcholinesterase inhibitor that increases circulating levels of acetylcholine. 


Question :

What is the importance of Huperzine A inhibiting an enzyme that breaks down acetylcholine and increasing circulating acetylcholine?  Why does that matter for gaining muscle, losing body fat, or body recomposition?


 Answer :

While acetylcholine is rarely discussed in the fitness and physique industry, it is a critical neurotransmitter and neuromodulator that functions in the central nervous system and peripheral nervous system. 


Multiple clinical studies have demonstrated the potential for Huperzine A to improve cognitive function and delay cognitive disease (Alzheimer’s Disease and Dementia) through a multi-target mechanism (improving acetylcholine levels, attenuating oxidative stress, alleviating mitochondria dysfunction, etc.). [115.] [116.] [117.] [118.] [119.] [120.] [121.] [122.]  Since it seems to be neuroprotective and combat cognitive disease in aging or sick individuals, it may have the potential to enhance multiple cognitive functions in healthy individuals.  Initially, cognitive function may not be considered valuable to physique enhancement, but in my opinion, it should be.  If acetylcholine is involved in the process of learning and memory [123.], attention [124.], and alertness after waking [125.], then maintaining adequate levels is vital for staying focused, dedicated, and consistent on the periodized training and nutrition program.  If acetylcholine is able to promote deep rapid-eye movement (REM) sleep [126.] and improve wakefulness, then an individual is less likely to skip training due to lack of sleep, recovery, or arousal.  Additionally, individuals in pursuit of physique enhancement or body recomposition may greatly benefit from the neuroprotective mechanisms and neurotransmitter chemicals related to Huperzine A.


Describing the complex relationship between acetylcholine and the neuromuscular junction as it pertains to skeletal muscle activation-contraction may be too detailed and long winded for this question.  In an effort to keep the answer brief and concise as possible, acetylcholine’s role in the first few steps of muscle contraction will be described below:

(1st) The action potential triggers the motor neuron to release acetylcholine,

(2nd) the acetylcholine reaches the neuromuscular junction and initiates an electrochemical process

{acetylcholine binding to its receptor is critical for the transition of a chemical signal to electrical signal},

(3rd) the signal / impulse travels through the muscle fiber via the T-tubules,

(4th) the impulse causes the sarcoplasmic reticulum to release Ca+ ions,

{calcium ions play a pivotal role in initiating muscular contractions}...

Once the Ca+ ions bind with troponin (removing the blocking action of tropomyosin from actin binding sites) the myosin is ready to bind with actin to form cross bridges and begin the muscle contraction process. Next, ATP (energy) binds to myosin.  Then, ATP is hydrolyzed to ADP and Pi to provide the energy necessary to cock its head in the high-energy position. Finally, releasing ADP and Pi as they pull actin filaments inwards and return to low energy position.  If there is sufficient Ca+ ions and ATP, then the process can be repeated.

** Please understand that the description provided for a muscle contraction was simplified as much as possible to communicate the importance of acetylcholine.**


Acknowledging this process highlights the importance of acetylcholine in triggering a sequence of steps that generate a muscular contraction.  If a supplement increases the amount of acetylcholine available for a skeletal muscle contraction, then it may enhance the skeletal muscles contractile force.  However, another way to appreciate acetylcholine’s potential benefits is to examine individuals with lower levels of acetylcholine and acetylcholine receptors.  A systematic review on age associated sarcopenia (muscle loss) discovered a relationship between acetylcholine receptor degeneration and muscle loss. [127.]  Overall, the research on sarcopenia (age related muscle loss) and dynapenia (age related loss of muscle strength) is steadily improving and scientists are beginning to understand more about the effect of aging on the neuromuscular mechanisms associated with the progressive loss of muscle tissue and function. [128.] [129.] [130.] [131.]  Since the current landscape provides enough data to confirm a potential loss of acetylcholine with aging, it may be a good idea to consider methods for increasing circulating acetylcholine levels. 


The benefits of increasing acetylcholine levels is quite obvious for aging individuals, but it may also be beneficial for young healthy individuals as well.  In my experience, Epi-Gro1000’s benefits are not controlled by the age of the individual.  Anecdotally, I have witness individuals from the age of 18 to 80 get positive results from supplementing with Epi-Gro1000.  The results varied slightly per person.  In large, Epi-Gro1000 seemed to produce a body composition effect or plateau breaking effect. 

Example A: One of my 40-year-old clients had been stuck at roughly the same weight and body composition for a few months.  They decided to add 2 servings (2 capsules each) of Epi-Gro1000 per day for 3 months.  Once they came in for their body composition (Parrillo 9-site skin-fold test) assessment, the results showed a significant increase in muscle mass and decrease in fat mass. 

Example B: Another individual was trying to get lean enough to have a defined 6-pack (under 10% body fat, using Parrillo 9-site skin-fold test) and had been plateaued between 13% and 15% for over 6 months.  This individual decided to use 3 capsules of Epi-Gro1000 with their morning coffee, before their traditional 30-minute walk and another 3 capsules with lunch or in the afternoon.  This protocol provided immediate results and this individual was able to meet their goal in 8 weeks.  Since they didn’t make any changes to their nutrition program, I was impressed by their results.  While these results may be great, these examples are only the tip of the iceberg.



Hopefully this detailed summary and review of the ingredients in Epi-Gro1000 will provide beneficial information to the individuals reading it.  I will continue to update the information regarding the ingredients in Swinney Nutrition supplements.  Additionally, I will continue to add beneficial information about human physiology, nutrition, and training.  In my opinion, constantly studying the physiological, biological, and chemical processes in the human body is vital in understanding the potential application of quality supplements.  Combining the broad knowledge with specific interest may improve an individual’s ability to develop practical methods to achieve desired goals.



  1. Charis M. Galanakis, Preface, Editor(s): Charis M. Galanakis, Polyphenols: Properties, Recovery, and Applications, Woodhead Publishing, 2018, Pages xv-xvii, ISBN 9780128135723.
  2. Zhang, Hua, and Rong Tsao. "Dietary polyphenols, oxidative stress and antioxidant and anti-inflammatory effects." Current Opinion in Food Science 8 (2016): 33-42.
  3. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S, Breteler MB. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris). 1997 Apr;153(3):185-92. PMID: 9296132.
  4. Truelsen T, Thudium D, Grønbaek M; Copenhagen City Heart Study. Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology. 2002 Nov 12;59(9):1313-9. doi: 10.1212/01.wnl.0000031421.50369.e7. PMID: 12427876.
  5. Aquilano K, Baldelli S, Rotilio G, Ciriolo MR. Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem Res. 2008 Dec;33(12):2416-26. doi: 10.1007/s11064-008-9697-6. Epub 2008 Apr 16. PMID: 18415676.
  6. Rossi L, Mazzitelli S, Arciello M, Capo CR, Rotilio G. Benefits from dietary polyphenols for brain aging and Alzheimer's disease. Neurochem Res. 2008 Dec;33(12):2390-400. doi: 10.1007/s11064-008-9696-7. Epub 2008 Apr 16. PMID: 18415677.
  7. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH. Curry consumption and cognitive function in the elderly. Am J Epidemiol. 2006 Nov 1;164(9):898-906. doi: 10.1093/aje/kwj267. Epub 2006 Jul 26. PMID: 16870699.
  8. Noguchi-Shinohara M, Yuki S, Dohmoto C, Ikeda Y, Samuraki M, Iwasa K, Yokogawa M, Asai K, Komai K, Nakamura H, Yamada M. Consumption of green tea, but not black tea or coffee, is associated with reduced risk of cognitive decline. PLoS One. 2014 May 14;9(5):e96013. doi: 10.1371/journal.pone.0096013. PMID: 24828424; PMCID: PMC4020750.
  9. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007 Feb 28;297(8):842-57. doi: 10.1001/jama.297.8.842. Erratum in: JAMA. 2008 Feb 20;299(7):765-6. PMID: 17327526.
  10. Ogle WO, Speisman RB, Ormerod BK. Potential of treating age-related depression and cognitive decline with nutraceutical approaches: a mini-review. Gerontology. 2013;59(1):23-31. doi: 10.1159/000342208. Epub 2012 Aug 30. PMID: 22947921.
  11. Zhou Y, Zheng J, Li Y, Xu DP, Li S, Chen YM, Li HB. Natural Polyphenols for Prevention and Treatment of Cancer. Nutrients. 2016 Aug 22;8(8):515. doi: 10.3390/nu8080515. PMID: 27556486; PMCID: PMC4997428.
  12. Wang S, Moustaid-Moussa N, Chen L, Mo H, Shastri A, Su R, Bapat P, Kwun I, Shen CL. Novel insights of dietary polyphenols and obesity. J Nutr Biochem. 2014 Jan;25(1):1-18. doi: 10.1016/j.jnutbio.2013.09.001. PMID: 24314860; PMCID: PMC3926750.
  13. Fujiki H, Sueoka E, Watanabe T, Suganuma M. Primary cancer prevention by green tea, and tertiary cancer prevention by the combination of green tea catechins and anticancer compounds. J Cancer Prev. 2015 Mar;20(1):1-4. doi: 10.15430/JCP.2015.20.1.1. PMID: 25853098; PMCID: PMC4384709.
  14. Guo R, Li W, Liu B, Li S, Zhang B, Xu Y. Resveratrol protects vascular smooth muscle cells against high glucose-induced oxidative stress and cell proliferation in vitro. Med Sci Monit Basic Res. 2014 Jun 27;20:82-92. doi: 10.12659/MSMBR.890858. PMID: 24971582; PMCID: PMC4095779.
  15. Zhang, Hui, et al. "GW27-e0657 Resveratrol Protects against oxidized LDL-induced foam cells formation and apoptosis through inhibition of ER stress and downregulation of CD36." Journal of the American College of Cardiology 68.16S (2016): C26-C26.
  16. Boullata JI, Hudson LM. Drug-nutrient interactions: a broad view with implications for practice. J Acad Nutr Diet. 2012 Apr;112(4):506-17. doi: 10.1016/j.jada.2011.09.002. Epub 2012 Feb 7. PMID: 22717215.
  17. Wang S, Sun Z, Dong S, Liu Y, Liu Y. Molecular interactions between (-)-epigallocatechin gallate analogs and pancreatic lipase. PLoS One. 2014 Nov 3;9(11):e111143. doi: 10.1371/journal.pone.0111143. PMID: 25365042; PMCID: PMC4218840.
  18. Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009 Nov-Dec;2(5):270-8. doi: 10.4161/oxim.2.5.9498. PMID: 20716914; PMCID: PMC2835915.
  19. Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 2017;1:35. doi: 10.1038/s41698-017-0038-6. Epub 2017 Sep 25. PMID: 28989978; PMCID: PMC5630227.
  20. Guo H, Chen Y, Liao L, Wu W. Resveratrol protects HUVECs from oxidized-LDL induced oxidative damage by autophagy upregulation via the AMPK/SIRT1 pathway. Cardiovasc Drugs Ther. 2013 Jun;27(3):189-98. doi: 10.1007/s10557-013-6442-4. PMID: 23358928.
  21. Weiskirchen S, Weiskirchen R. Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy? Adv Nutr. 2016 Jul 15;7(4):706-18. doi: 10.3945/an.115.011627. PMID: 27422505; PMCID: PMC4942868.
  22. Xiao JB, Högger P. Dietary polyphenols and type 2 diabetes: current insights and future perspectives. Curr Med Chem. 2015;22(1):23-38. doi: 10.2174/0929867321666140706130807. PMID: 25005188.
  23. Jakobek L. Interactions of polyphenols with carbohydrates, lipids and proteins. Food Chem. 2015 May 15;175:556-67. doi: 10.1016/j.foodchem.2014.12.013. Epub 2014 Dec 11. PMID: 25577120.
  24. Zhang B, Deng Z, Ramdath DD, Tang Y, Chen PX, Liu R, Liu Q, Tsao R. Phenolic profiles of 20 Canadian lentil cultivars and their contribution to antioxidant activity and inhibitory effects on α-glucosidase and pancreatic lipase. Food Chem. 2015 Apr 1;172:862-72. doi: 10.1016/j.foodchem.2014.09.144. Epub 2014 Oct 5. PMID: 25442631.
  25. Barrett, Ann H., Nicole F. Farhadi, and Tracey J. Smith. "Slowing starch digestion and inhibiting digestive enzyme activity using plant flavanols/tannins—A review of efficacy and mechanisms." Lwt 87 (2018): 394-399.
  26. Yamagata K, Tagami M, Yamori Y. Dietary polyphenols regulate endothelial function and prevent cardiovascular disease. Nutrition. 2015 Jan;31(1):28-37. doi: 10.1016/j.nut.2014.04.011. Epub 2014 Apr 30. PMID: 25466651.
  27. Pandey, Kanti Bhooshan, and Syed Ibrahim Rizvi. “Plant polyphenols as dietary antioxidants in human health and disease.” Oxidative medicine and cellular longevity vol. 2,5 (2009): 270-8. doi:10.4161/oxim.2.5.9498
  28. Hertog MG, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, Giampaoli S, Jansen A, Menotti A, Nedeljkovic S, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med. 1995 Feb 27;155(4):381-6. Erratum in: Arch Intern Med 1995 Jun 12;155(11):1184. PMID: 7848021.
  29. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993 Oct 23;342(8878):1007-11. doi: 10.1016/0140-6736(93)92876-u. PMID: 8105262.
  30. Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ. 1996 Feb 24;312(7029):478-81. doi: 10.1136/bmj.312.7029.478. PMID: 8597679; PMCID: PMC2349921.
  31. Joshipura KJ, Hu FB, Manson JE, Stampfer MJ, Rimm EB, Speizer FE, Colditz G, Ascherio A, Rosner B, Spiegelman D, Willett WC. The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med. 2001 Jun 19;134(12):1106-14. doi: 10.7326/0003-4819-134-12-200106190-00010. PMID: 11412050.
  32. Keli SO, Hertog MG, Feskens EJ, Kromhout D. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med. 1996 Mar 25;156(6):637-42. PMID: 8629875.
  33. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004 May;79(5):727-47. doi: 10.1093/ajcn/79.5.727. PMID: 15113710.
  34. Vogiatzoglou A, Mulligan AA, Luben RN, Lentjes MA, Heiss C, Kelm M, Merx MW, Spencer JP, Schroeter H, Kuhnle GG. Assessment of the dietary intake of total flavan-3-ols, monomeric flavan-3-ols, proanthocyanidins and theaflavins in the European Union. Br J Nutr. 2014 Apr 28;111(8):1463-73. doi: 10.1017/S0007114513003930. Epub 2013 Dec 13. PMID: 24331295.
  35. Vogiatzoglou A, Mulligan AA, Bhaniani A, Lentjes MAH, McTaggart A, Luben RN, Heiss C, Kelm M, Merx MW, Spencer JPE, Schroeter H, Khaw KT, Kuhnle GGC. Associations between flavan-3-ol intake and CVD risk in the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk). Free Radic Biol Med. 2015 Jul;84:1-10. doi: 10.1016/j.freeradbiomed.2015.03.005. Epub 2015 Mar 17. PMID: 25795512; PMCID: PMC4503814.
  36. Heiss C, Keen CL, Kelm M. Flavanols and cardiovascular disease prevention. Eur Heart J. 2010 Nov;31(21):2583-92. doi: 10.1093/eurheartj/ehq332. Epub 2010 Sep 18. PMID: 20852295.
  37. Schroeter H, Heiss C, Spencer JP, Keen CL, Lupton JR, Schmitz HH. Recommending flavanols and procyanidins for cardiovascular health: current knowledge and future needs. Mol Aspects Med. 2010 Dec;31(6):546-57. doi: 10.1016/j.mam.2010.09.008. Epub 2010 Sep 18. PMID: 20854838.
  38. Heiss, Christian, et al. "Vascular effects of cocoa rich in flavan-3-ols." Jama 290.8 (2003): 1030-1031.
  39. Schroeter, Hagen, et al. "(–)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans." Proceedings of the National Academy of Sciences 103.4 (2006): 1024-1029.
  40. Thithapandha A. Effect of caffeine on the bioavailability and pharmacokinetics of aspirin. J Med Assoc Thai. 1989 Oct;72(10):562-6. PMID: 2584901.
  41. Yoovathaworn KC, Sriwatanakul K, Thithapandha A. Influence of caffeine on aspirin pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1986 Jan-Mar;11(1):71-6. doi: 10.1007/BF03189777. PMID: 3720797.
  42. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet. 1971 Jun 5;1(7710):1143-5. doi: 10.1016/s0140-6736(71)91658-8. PMID: 4102857.
  43. Bang HO, Dyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast Eskimos. Acta Med Scand. 1972 Jul-Aug;192(1-2):85-94. doi: 10.1111/j.0954-6820.1972.tb04782.x. PMID: 5052396.
  44. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr. 1975 Sep;28(9):958-66. doi: 10.1093/ajcn/28.9.958. PMID: 1163480.
  45. Bang HO, Dyerberg J, Hjøorne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand. 1976;200(1-2):69-73. doi: 10.1111/j.0954-6820.1976.tb08198.x. PMID: 961471.
  46. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. 1978 Jul 15;2(8081):117-9. doi: 10.1016/s0140-6736(78)91505-2. PMID: 78322.
  47. L. McCullough, K. Chevaux, L. Jackson et al., “Hypertension, the Kuna, and the epidemiology of flavanols,” Journal of Cardio- vascular Pharmacology, vol. 47, no. 2, pp. S103–S109, 2006.
  48. Hollenberg NK, Martinez G, McCullough M, Meinking T, Passan D, Preston M, Rivera A, Taplin D, Vicaria-Clement M. Aging, acculturation, salt intake, and hypertension in the Kuna of Panama. Hypertension. 1997 Jan;29(1 Pt 2):171-6. doi: 10.1161/01.hyp.29.1.171. PMID: 9039098.
  49. Chevaux KA, Jackson L, Villar ME, Mundt JA, Commisso JF, Adamson GE, McCullough ML, Schmitz HH, Hollenberg NK. Proximate, mineral, and procyanidin content of certain foods and beverages consumed by the Kuna Amerinds of Panama. J Food Comp Anal. 2001;14:553–63.
  50. Hollenberg NK, Fisher ND, McCullough ML. Flavanols, the Kuna, cocoa consumption, and nitric oxide. J Am Soc Hypertens. 2009 Mar-Apr;3(2):105-12. doi: 10.1016/j.jash.2008.11.001. Epub 2009 Feb 20. PMID: 20409950; PMCID: PMC3835452.
  51. Belˇscˇak, D. Komes, D. Horzˇic ́, K. K. Ganic ́, and D. Karlovic ́, “Comparative study of commercially available cocoa products in terms of their bioactive composition,” Food Research Interna- tional, vol. 42, no. 5-6, pp. 707–716, 2009.
  52. Hollenberg NK. Organ systems dependent on nitric oxide and the potential for nitric oxide-targeted therapies in related diseases. J Clin Hypertens (Greenwich). 2006 Dec;8(12 Suppl 4):63-73. doi: 10.1111/j.1524-6175.2006.06042.x. PMID: 17170607; PMCID: PMC8109608.
  53. Gutierrez-Salmean, Gabriela et al. “Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation.” The Journal of nutritional biochemistry vol. 25,1 (2014): 91-4. doi:10.1016/j.jnutbio.2013.09.007
  54. Taub PR, Ramirez-Sanchez I, Ciaraldi TP, Perkins G, Murphy AN, Naviaux R, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci. 2012 Feb;5(1):43-7. doi: 10.1111/j.1752-8062.2011.00357.x. Epub 2011 Nov 7. PMID: 22376256; PMCID: PMC5439909.
  55. Nogueira L, Ramirez-Sanchez I, Perkins GA, Murphy A, Taub PR, Ceballos G, Villarreal FJ, Hogan MC, Malek MH. (-)-Epicatechin enhances fatigue resistance and oxidative capacity in mouse muscle. J Physiol. 2011 Sep 15;589(Pt 18):4615-31. doi: 10.1113/jphysiol.2011.209924. Epub 2011 Jul 25. PMID: 21788351; PMCID: PMC3208228.
  56. Ramirez-Sanchez I, Maya L, Ceballos G, Villarreal F. (-)-epicatechin activation of endothelial cell endothelial nitric oxide synthase, nitric oxide, and related signaling pathways. Hypertension. 2010 Jun;55(6):1398-405. doi: 10.1161/HYPERTENSIONAHA.109.147892. Epub 2010 Apr 19. PMID: 20404222; PMCID: PMC2874202.
  57. Yamazaki KG, Romero-Perez D, Barraza-Hidalgo M, Cruz M, Rivas M, Cortez-Gomez B, Ceballos G, Villarreal F. Short- and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H761-7. doi: 10.1152/ajpheart.00413.2008. Epub 2008 Jun 20. PMID: 18567705; PMCID: PMC2519218.
  58. Yamazaki KG, Taub PR, Barraza-Hidalgo M, Rivas MM, Zambon AC, Ceballos G, Villarreal FJ. Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion. J Am Coll Cardiol. 2010 Jun 22;55(25):2869-76. doi: 10.1016/j.jacc.2010.01.055. PMID: 20579545; PMCID: PMC2915587.
  59. Yamazaki, Katrina Go et al. “Intravenous (-)-epicatechin reduces myocardial ischemic injury by protecting mitochondrial function.” International journal of cardiology vol. 175,2 (2014): 297-306. doi:10.1016/j.ijcard.2014.05.009
  60. Prince PS. A biochemical, electrocardiographic, electrophoretic, histopathological and in vitro study on the protective effects of (-)epicatechin in isoproterenol-induced myocardial infarcted rats. Eur J Pharmacol. 2011 Dec 5;671(1-3):95-101. doi: 10.1016/j.ejphar.2011.09.036. Epub 2011 Sep 21. PMID: 21958876.
  61. Carlson JR, Bauer BA, Vincent A, Limburg PJ, Wilson T. Reading the tea leaves: anticarcinogenic properties of (-)-epigallocatechin-3-gallate. Mayo Clin Proc. 2007 Jun;82(6):725-32. doi: 10.4065/82.6.725. PMID: 17550753.
  62. Yang CS, Wang H. Cancer Preventive Activities of Tea Catechins. Molecules. 2016 Dec 9;21(12):1679. doi: 10.3390/molecules21121679. PMID: 27941682; PMCID: PMC6273642.
  63. Xiang LP, Wang A, Ye JH, Zheng XQ, Polito CA, Lu JL, Li QS, Liang YR. Suppressive Effects of Tea Catechins on Breast Cancer. Nutrients. 2016 Jul 28;8(8):458. doi: 10.3390/nu8080458. PMID: 27483305; PMCID: PMC4997373.
  64. Beltz LA, Bayer DK, Moss AL, Simet IM. Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem. 2006 Sep;6(5):389-406. doi: 10.2174/187152006778226468. PMID: 17017850.
  65. Ahmad N, Mukhtar H. Green tea polyphenols and cancer: biologic mechanisms and practical implications. Nutr Rev. 1999 Mar;57(3):78-83. doi: 10.1111/j.1753-4887.1999.tb06927.x. PMID: 10101921.
  66. Gupta, D. A., et al. "Green tea: A review on its natural anti-oxidant therapy and cariostatic benefits." Biol. Sci. Pharm. Res2 (2014): 8-12.
  67. Bernatoniene J, Kopustinskiene DM. The Role of Catechins in Cellular Responses to Oxidative Stress. Molecules. 2018 Apr 20;23(4):965. doi: 10.3390/molecules23040965. PMID: 29677167; PMCID: PMC6017297.
  68. Masek, Anna, et al. "Antioxidant and antiradical properties of green tea extract compounds." Int. J. Electrochem. Sci 12 (2017): 6600-6610.
  69. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011 Dec 15;82(12):1807-21. doi: 10.1016/j.bcp.2011.07.093. Epub 2011 Jul 30. PMID: 21827739; PMCID: PMC4082721.
  70. Reygaert WC. Green Tea Catechins: Their Use in Treating and Preventing Infectious Diseases. Biomed Res Int. 2018 Jul 17;2018:9105261. doi: 10.1155/2018/9105261. PMID: 30105263; PMCID: PMC6076941.
  71. Pervin M, Unno K, Takagaki A, Isemura M, Nakamura Y. Function of Green Tea Catechins in the Brain: Epigallocatechin Gallate and its Metabolites. Int J Mol Sci. 2019 Jul 25;20(15):3630. doi: 10.3390/ijms20153630. PMID: 31349535; PMCID: PMC6696481.
  72. Niedzwiecki A, Roomi MW, Kalinovsky T, Rath M. Anticancer Efficacy of Polyphenols and Their Combinations. Nutrients. 2016 Sep 9;8(9):552. doi: 10.3390/nu8090552. PMID: 27618095; PMCID: PMC5037537.
  73. Yanagimoto K, Ochi H, Lee KG, Shibamoto T. Antioxidative activities of volatile extracts from green tea, oolong tea, and black tea. J Agric Food Chem. 2003 Dec 3;51(25):7396-401. doi: 10.1021/jf030127i. PMID: 14640590.
  74. Yang Y, Qin YJ, Yip YW, Chan KP, Chu KO, Chu WK, Ng TK, Pang CP, Chan SO. Green tea catechins are potent anti-oxidants that ameliorate sodium iodate-induced retinal degeneration in rats. Sci Rep. 2016 Jul 7;6:29546. doi: 10.1038/srep29546. PMID: 27383468; PMCID: PMC4935886.
  75. Cavet ME, Harrington KL, Vollmer TR, Ward KW, Zhang JZ. Anti-inflammatory and anti-oxidative effects of the green tea polyphenol epigallocatechin gallate in human corneal epithelial cells. Mol Vis. 2011 Feb 18;17:533-42. PMID: 21364905; PMCID: PMC3044696.
  76. Yang CS, Lambert JD, Sang S. Antioxidative and anti-carcinogenic activities of tea polyphenols. Arch Toxicol. 2009 Jan;83(1):11-21. doi: 10.1007/s00204-008-0372-0. Epub 2008 Nov 12. PMID: 19002670; PMCID: PMC2820244.
  77. Liu D, Perkins JT, Hennig B. EGCG prevents PCB-126-induced endothelial cell inflammation via epigenetic modifications of NF-κB target genes in human endothelial cells. J Nutr Biochem. 2016 Feb;28:164-70. doi: 10.1016/j.jnutbio.2015.10.003. Epub 2015 Oct 26. PMID: 26878794; PMCID: PMC4757812.
  78. Hamilton-Miller JMT. Anti-cariogenic properties of tea (Camellia sinensis). J Med Microbiol. 2001 Apr;50(4):299-302. doi: 10.1099/0022-1317-50-4-299. PMID: 11289514.
  79. Maity R, Chatterjee M, Banerjee A, Das A, Mishra R, Mazumder S, Chanda N. Gold nanoparticle-assisted enhancement in the anti-cancer properties of theaflavin against human ovarian cancer cells. Mater Sci Eng C Mater Biol Appl. 2019 Nov;104:109909. doi: 10.1016/j.msec.2019.109909. Epub 2019 Jun 22. PMID: 31499983.
  80. Subramani, Chitra, and Ramesh Kumar Natesh. "Molecular mechanisms and biological implications of green tea polyphenol,(-)-epigallocatechin-3-gallate." International Journal of Pharma Bioscience and Technology 1.2 (2013): 54-63.
  81. Lombo C, Morgado C, Tavares I, Neves D. Effects of prolonged ingestion of epigallocatechin gallate on diabetes type 1-induced vascular modifications in the erectile tissue of rats. Int J Impot Res. 2016 Jul;28(4):133-8. doi: 10.1038/ijir.2016.19. Epub 2016 May 12. PMID: 27169491.
  82. Othman AI, El-Sawi MR, El-Missiry MA, Abukhalil MH. Epigallocatechin-3-gallate protects against diabetic cardiomyopathy through modulating the cardiometabolic risk factors, oxidative stress, inflammation, cell death and fibrosis in streptozotocin-nicotinamide-induced diabetic rats. Biomed Pharmacother. 2017 Oct;94:362-373. doi: 10.1016/j.biopha.2017.07.129. Epub 2017 Aug 1. PMID: 28772214.
  83. Suzuki T, Pervin M, Goto S, Isemura M, Nakamura Y. Beneficial Effects of Tea and the Green Tea Catechin Epigallocatechin-3-gallate on Obesity. Molecules. 2016 Sep 29;21(10):1305. doi: 10.3390/molecules21101305. PMID: 27689985; PMCID: PMC6274011.
  84. Friedrich M, Petzke KJ, Raederstorff D, Wolfram S, Klaus S. Acute effects of epigallocatechin gallate from green tea on oxidation and tissue incorporation of dietary lipids in mice fed a high-fat diet. Int J Obes (Lond). 2012 May;36(5):735-43. doi: 10.1038/ijo.2011.136. Epub 2011 Jul 12. PMID: 21750518.
  85. Lee MS, Kim CT, Kim Y. Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice. Ann Nutr Metab. 2009;54(2):151-7. doi: 10.1159/000214834. Epub 2009 Apr 22. PMID: 19390166.
  86. Yokogoshi, H. "Health Benefits of Green Tea: An Evidence-Based Approach." (2016).
  87. Pervin M, Unno K, Ohishi T, Tanabe H, Miyoshi N, Nakamura Y. Beneficial Effects of Green Tea Catechins on Neurodegenerative Diseases. Molecules. 2018 May 29;23(6):1297. doi: 10.3390/molecules23061297. PMID: 29843466; PMCID: PMC6099654.
  88. Xicota L, Rodriguez-Morato J, Dierssen M, de la Torre R. Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease. Curr Drug Targets. 2017;18(2):174-195. doi: 10.2174/1389450116666150825113655. PMID: 26302801.
  89. Ding ML, Ma H, Man YG, Lv HY. Protective effects of a green tea polyphenol, epigallocatechin-3-gallate, against sevoflurane-induced neuronal apoptosis involve regulation of CREB/BDNF/TrkB and PI3K/Akt/mTOR signalling pathways in neonatal mice. Can J Physiol Pharmacol. 2017 Dec;95(12):1396-1405. doi: 10.1139/cjpp-2016-0333. Epub 2017 Jul 5. PMID: 28679060.
  90. He Y, Tan D, Bai B, Wu Z, Ji S. Epigallocatechin-3-gallate attenuates acrylamide-induced apoptosis and astrogliosis in rat cerebral cortex. Toxicol Mech Methods. 2017 May;27(4):298-306. doi: 10.1080/15376516.2017.1279251. Epub 2017 Jan 22. PMID: 28056603.
  91. Nomura S, Ichinose T, Jinde M, Kawashima Y, Tachiyashiki K, Imaizumi K. Tea catechins enhance the mRNA expression of uncoupling protein 1 in rat brown adipose tissue. J Nutr Biochem. 2008 Dec;19(12):840-7. doi: 10.1016/j.jnutbio.2007.11.005. Epub 2008 May 13. PMID: 18479902.
  92. Yan J, Zhao Y, Zhao B. Green tea catechins prevent obesity through modulation of peroxisome proliferator-activated receptors. Sci China Life Sci. 2013 Sep;56(9):804-10. doi: 10.1007/s11427-013-4512-2. Epub 2013 Jul 12. PMID: 23864528.
  93. Chen N, Bezzina R, Hinch E, Lewandowski PA, Cameron-Smith D, Mathai ML, Jois M, Sinclair AJ, Begg DP, Wark JD, Weisinger HS, Weisinger RS. Green tea, black tea, and epigallocatechin modify body composition, improve glucose tolerance, and differentially alter metabolic gene expression in rats fed a high-fat diet. Nutr Res. 2009 Nov;29(11):784-93. doi: 10.1016/j.nutres.2009.10.003. PMID: 19932867.
  94. Wang H, Wen Y, Du Y, Yan X, Guo H, Rycroft JA, Boon N, Kovacs EM, Mela DJ. Effects of catechin enriched green tea on body composition. Obesity (Silver Spring). 2010 Apr;18(4):773-9. doi: 10.1038/oby.2009.256. Epub 2009 Aug 13. PMID: 19680234.
  95. Nagao T, Hase T, Tokimitsu I. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring). 2007 Jun;15(6):1473-83. doi: 10.1038/oby.2007.176. PMID: 17557985.
  96. Kubota K, Sumi S, Tojo H, Sumi-Inoue Y, I-Chin H, Oi Y, Fujita H, Urata H. Improvements of mean body mass index and body weight in preobese and overweight Japanese adults with black Chinese tea (Pu-Erh) water extract. Nutr Res. 2011 Jun;31(6):421-8. doi: 10.1016/j.nutres.2011.05.004. Epub 2011 Jun 17. Erratum in: Nutr Res. 2012 Jun;32(6):470. PMID: 21745623.
  97. Chen IJ, Liu CY, Chiu JP, Hsu CH. Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2016 Jun;35(3):592-9. doi: 10.1016/j.clnu.2015.05.003. Epub 2015 May 29. PMID: 26093535.
  98. Mielgo-Ayuso J, Barrenechea L, Alcorta P, Larrarte E, Margareto J, Labayen I. Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial. Br J Nutr. 2014 Apr 14;111(7):1263-71. doi: 10.1017/S0007114513003784. Epub 2013 Dec 3. PMID: 24299662.
  99. Jurgens TM, Whelan AM, Killian L, Doucette S, Kirk S, Foy E. Green tea for weight loss and weight maintenance in overweight or obese adults. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD008650. doi: 10.1002/14651858.CD008650.pub2. PMID: 23235664; PMCID: PMC8406948.
  100. Vázquez Cisneros LC, López-Uriarte P, López-Espinoza A, Navarro Meza M, Espinoza-Gallardo AC, Guzmán Aburto MB. Efectos del té verde y su contenido de galato de epigalocatequina (EGCG) sobre el peso corporal y la masa grasa en humanos. Una revisión sistemática [Effects of green tea and its epigallocatechin (EGCG) content on body weight and fat mass in humans: a systematic review]. Nutr Hosp. 2017 Jun 5;34(3):731-737. Spanish. doi: 10.20960/nh.753. PMID: 28627214.
  101. Li X, Wang W, Hou L, Wu H, Wu Y, Xu R, Xiao Y, Wang X. Does tea extract supplementation benefit metabolic syndrome and obesity? A systematic review and meta-analysis. Clin Nutr. 2020 Apr;39(4):1049-1058. doi: 10.1016/j.clnu.2019.05.019. Epub 2019 May 24. PMID: 31174941.
  102. Ashida H, Furuyashiki T, Nagayasu H, Bessho H, Sakakibara H, Hashimoto T, Kanazawa K. Anti-obesity actions of green tea: possible involvements in modulation of the glucose uptake system and suppression of the adipogenesis-related transcription factors. Biofactors. 2004;22(1-4):135-40. doi: 10.1002/biof.5520220126. PMID: 15630268.
  103. Cao H, Hininger-Favier I, Kelly MA, Benaraba R, Dawson HD, Coves S, Roussel AM, Anderson RA. Green tea polyphenol extract regulates the expression of genes involved in glucose uptake and insulin signaling in rats fed a high fructose diet. J Agric Food Chem. 2007 Jul 25;55(15):6372-8. doi: 10.1021/jf070695o. Epub 2007 Jul 6. PMID: 17616136.
  104. Hossain SJ, Kato H, Aoshima H, Yokoyama T, Yamada M, Hara Y. Polyphenol-induced inhibition of the response of na(+)/glucose cotransporter expressed in Xenopus oocytes. J Agric Food Chem. 2002 Aug 28;50(18):5215-9. doi: 10.1021/jf020252e. PMID: 12188632.
  105. Shimizu M, Kobayashi Y, Suzuki M, Satsu H, Miyamoto Y. Regulation of intestinal glucose transport by tea catechins. Biofactors. 2000;13(1-4):61-5. doi: 10.1002/biof.5520130111. PMID: 11237201.
  106. Howes MR, Fang R, Houghton PJ. Effect of Chinese Herbal Medicine on Alzheimer's Disease. Int Rev Neurobiol. 2017;135:29-56. doi: 10.1016/bs.irn.2017.02.003. Epub 2017 Mar 24. PMID: 28807163.
  107. Murphy RA, Sarpong R. Heathcock-inspired strategies for the synthesis of fawcettimine-type Lycopodium alkaloids. Chemistry. 2014 Jan 3;20(1):42-56. doi: 10.1002/chem.201303975. Epub 2013 Dec 5. PMID: 24311383.
  108. Wu TY, Chen CP, Jinn TR. Traditional Chinese medicines and Alzheimer's disease. Taiwan J Obstet Gynecol. 2011 Jun;50(2):131-5. doi: 10.1016/j.tjog.2011.04.004. Erratum in: Taiwan J Obstet Gynecol. 2011 Sep;50(3):408. Chen, Chip-Ping [corrected to Chen, Chih-Ping]. PMID: 21791295.
  109. Yang, Guoyan et al. “Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.” PloS one vol. 8,9 e74916. 23 Sep. 2013, doi:10.1371/journal.pone.0074916
  110. Nett RS, Dho Y, Low YY, Sattely ES. A metabolic regulon reveals early and late acting enzymes in neuroactive Lycopodium alkaloid biosynthesis. Proc Natl Acad Sci U S A. 2021 Jun 15;118(24):e2102949118. doi: 10.1073/pnas.2102949118. PMID: 34112718; PMCID: PMC8214681.
  111. Callizot N, Campanari ML, Rouvière L, Jacquemot G, Henriques A, Garayev E, Poindron P. Huperzia serrata Extract 'NSP01' With Neuroprotective Effects-Potential Synergies of Huperzine A and Polyphenols. Front Pharmacol. 2021 Aug 30;12:681532. doi: 10.3389/fphar.2021.681532. PMID: 34526893; PMCID: PMC8435632.
  112. Kong YR, Tay KC, Su YX, Wong CK, Tan WN, Khaw KY. Potential of Naturally Derived Alkaloids as Multi-Targeted Therapeutic Agents for Neurodegenerative Diseases. Molecules. 2021 Jan 30;26(3):728. doi: 10.3390/molecules26030728. PMID: 33573300; PMCID: PMC7866829.
  113. Pharmacol Sin. 2006 Jan;27(1):1-26. doi: 10.1111/j.1745-7254.2006.00255.x. PMID: 16364207.
  114. Zhu HF, Yan PW, Wang LJ, Liu YT, Wen J, Zhang Q, Fan YX, Luo YH. Protective properties of Huperzine A through activation Nrf2/ARE-mediated transcriptional response in X-rays radiation-induced NIH3T3 cells. J Cell Biochem. 2018 Nov;119(10):8359-8367. doi: 10.1002/jcb.26919. Epub 2018 Jun 22. PMID: 29932247.
  115. Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL, Wang GQ, Su XQ, Zhong XS, Cheng RY, Xu WA, Li JX, Feng B. Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao. 1999 Jun;20(6):486-90. Erratum in: Chung Kuo Yao Li Hsueh Pao 1999 Aug;20(8):732. PMID: 10678137.
  116. Ye JW, Cai JX, Wang LM, Tang XC. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J Pharmacol Exp Ther. 1999 Feb;288(2):814-9. PMID: 9918593.
  117. Howes MJ, Perry E. The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging. 2011 Jun 1;28(6):439-68. doi: 10.2165/11591310-000000000-00000. PMID: 21639405.
  118. Sheng L, Qu Y, Yan J, Liu GY, Wang WL, Wang YJ, Wang HY, Zhang MQ, Lu C, Liu Y, Jia JY, Hu CY, Li XN, Yu C, Xu HR. Population pharmacokinetic modeling and simulation of huperzine A in elderly Chinese subjects. Acta Pharmacol Sin. 2016 Jul;37(7):994-1001. doi: 10.1038/aps.2016.24. Epub 2016 May 16. PMID: 27180987; PMCID: PMC4933756.
  119. Mei Z, Zheng P, Tan X, Wang Y, Situ B. Huperzine A alleviates neuroinflammation, oxidative stress and improves cognitive function after repetitive traumatic brain injury. Metab Brain Dis. 2017 Dec;32(6):1861-1869. doi: 10.1007/s11011-017-0075-4. Epub 2017 Jul 26. PMID: 28748496.
  120. Zhu N, Lin J, Wang K, Wei M, Chen Q, Wang Y. Huperzine A protects neural stem cells against Aβ-induced apoptosis in a neural stem cells and microglia co-culture system. Int J Clin Exp Pathol. 2015 Jun 1;8(6):6425-33. PMID: 26261518; PMCID: PMC4525852.
  121. Tao LX, Huang XT, Chen YT, Tang XC, Zhang HY. Acetylcholinesterase-independent protective effects of huperzine A against iron overload-induced oxidative damage and aberrant iron metabolism signaling in rat cortical neurons. Acta Pharmacol Sin. 2016 Nov;37(11):1391-1400. doi: 10.1038/aps.2016.78. Epub 2016 Aug 8. PMID: 27498774; PMCID: PMC5099413.
  122. Wang R, Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals. 2005;14(1-2):71-82. doi: 10.1159/000085387. PMID: 15956816.
  123. Ridley RM, Bowes PM, Baker HF, Crow TJ. An involvement of acetylcholine in object discrimination learning and memory in the marmoset. Neuropsychologia. 1984;22(3):253-63. doi: 10.1016/0028-3932(84)90073-3. PMID: 6431311.
  124. Himmelheber AM, Sarter M, Bruno JP. Increases in cortical acetylcholine release during sustained attention performance in rats. Brain Res Cogn Brain Res. 2000 Jun;9(3):313-25. doi: 10.1016/s0926-6410(00)00012-4. PMID: 10808142.
  125. Jones BE. From waking to sleeping: neuronal and chemical substrates. Trends Pharmacol Sci. 2005 Nov;26(11):578-86. doi: 10.1016/j.tips.2005.09.009. Epub 2005 Sep 23. Erratum in: Trends Pharmacol Sci. 2006 Apr;27(4):189. PMID: 16183137.
  126. Platt B, Riedel G. The cholinergic system, EEG and sleep. Behav Brain Res. 2011 Aug 10;221(2):499-504. doi: 10.1016/j.bbr.2011.01.017. Epub 2011 Jan 14. PMID: 21238497.
  127. Bao Z, Cui C, Chow SK, Qin L, Wong RMY, Cheung WH. AChRs Degeneration at NMJ in Aging-Associated Sarcopenia-A Systematic Review. Front Aging Neurosci. 2020 Dec 10;12:597811. doi: 10.3389/fnagi.2020.597811. PMID: 33362532; PMCID: PMC7759742.
  128. Deschenes MR, Flannery R, Hawbaker A, Patek L, Mifsud M. Adaptive Remodeling of the Neuromuscular Junction with Aging. Cells. 2022 Mar 29;11(7):1150. doi: 10.3390/cells11071150. PMID: 35406714; PMCID: PMC8997609.
  129. Delbono O, Rodrigues ACZ, Bonilla HJ, Messi ML. The emerging role of the sympathetic nervous system in skeletal muscle motor innervation and sarcopenia. Ageing Res Rev. 2021 May;67:101305. doi: 10.1016/j.arr.2021.101305. Epub 2021 Feb 18. PMID: 33610815; PMCID: PMC8049122.
  130. Rodríguez Cruz PM, Cossins J, Beeson D, Vincent A. The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing Synaptic Formation and Homeostasis. Front Mol Neurosci. 2020 Dec 3;13:610964. doi: 10.3389/fnmol.2020.610964. PMID: 33343299; PMCID: PMC7744297.
  131. Clark BC, Manini TM. What is dynapenia? Nutrition. 2012 May;28(5):495-503. doi: 10.1016/j.nut.2011.12.002. PMID: 22469110; PMCID: PMC3571692.